Navigation Links
Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine

BEDMINSTER, N.J., March 19, 2012 /PRNewswire/ -- Nautilus Neurosciences announced today that their Canadian promotional partner, Tribute Pharmaceuticals, a wholly owned subsidiary of Stellar Pharmaceuticals, was granted a Notice of Compliance (NOC) approval from Health Canada for CAMBIA® (diclofenac potassium for oral solution) in the treatment of acute migraine with or without aura in adults. CAMBIA® is expected to be launched in Canada during the second half of 2012. CAMBIA® has been available to patients in the United States since May 2010.

Nautilus Neurosciences has exclusive marketing rights for CAMBIA® in the United States and Canada, which they obtained from APR, a Swiss drug delivery and drug development company. Patents have been granted that protect the product in the United States through 2026.

"We congratulate our partners at Tribute Pharmaceuticals on the Health Canada approval and look forward to continuing to work with them on the Canadian launch of CAMBIA®. We are excited that CAMBIA® will be available as a treatment option for physicians and patients in Canada," said William Maichle, the CEO of Nautilus Neurosciences. Mr. Maichle highlighted, "With CAMBIA® now approved in both the United States and Canada, this marks another major milestone in the evolution of Nautilus to a best-in-class neurology-focused specialty pharmaceutical company."

Mr. Maichle added, "Looking forward, our strategy is to build an increasingly valuable company through the addition of complementary neurology-targeted therapies through in-licensing and acquisition opportunities. Mr. Maichle concluded, "[I] expect Nautilus Neurosciences to experience record growth in 2012 as CAMBIA® continues to fill an important unmet need for patients suffering from the debilitating effects of migraine."


CAMBIA® (diclofenac potassium for oral solution) is the lead product from Nautilus Neurosciences and has been available for sale in the United States since May 2010. It is indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

CAMBIA® is a novel patented formulation of diclofenac potassium that is the only prescription-strength non-steroidal anti-inflammatory drug (NSAID) approved and indicated by the FDA for the acute treatment of migraine. Engineered using Dynamic Buffering Technology™, CAMBIA® is specifically designed for fast, effective relief from the symptoms of migraine. Working to treat the underlying pathophysiology of migraine, CAMBIA® has proven to be clinically effective in reducing migraine pain in as fast as 15 minutes.

About Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is sponsored by Tailwind Capital and Galen Partners.

For more information about Nautilus Neurosciences, please visit:

About Stellar Pharmaceuticals Inc.

Stellar Pharmaceuticals and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products, with its primary focus on the Canadian market.

For further information on Stellar Pharmaceuticals, visit, and for information on its subsidiary, please visit

About Applied Pharma Research

APR Applied Pharma Research SA is an independent, international, vertically integrated drug delivery and drug development company in healthcare, with registered offices in Switzerland and the United States. It is focused on the research and development of innovative and patented drug delivery systems as well as innovative pharmaceutical products primarily for oral and topical administration.

For more information about APR, please visit  

SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
2. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
3. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
4. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
5. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
7. Proteonomix Announces a Private Placement of $3.8 Million
8. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
9. ARUP Laboratories Announces Creation of Business Innovations Division
10. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
11. Regeneron Announces March 2012 Investor Conference Presentations
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
Breaking Biology News(10 mins):